High-frequency rTMS
Devicerepetitive transcranial magnetic stimulation
NCT Number: NCT04318977
Treatment of depression with repetitive transcranial magnetic stimulation (rTMS) has shown high evidence using high-frequency left dorsolateral prefrontal cortex (DLPFC) stimulation. The treatment of negative symptoms with the same protocol in schizophrenia is considered as possible effective. Theta burst stimulation is a new protocol which is characterized by shorter sessions showing first evidence that it's efficacy is comparable to the high-frequency rTMS. In this randomized placebo-controlled study the efficacy of high-frequency rTMS and TBS are evaluated.
This study is active but is not currently recruiting participants.
Notify Me18 year–75 year
All sexes
Interventional
Not applicable
Brno University Hospital, Brno, Czechia
In this randomized placebo-controlled study the efficacy of high-frequency rTMS and TBS are evaluated. The active study arms are high-frequency rTMS and iTBS of the left dorsolateral prefrontal cortex to treat negative symptoms in schizophrenia. The control arm will include the same number of patients as each active arm and includes both sham rTMS and sham iTBS in the same proportion as the active treatments.
Standards of the trial will be harmonized across four clinical centers with the aim to pool data for analysis. Each center is responsible for ethical approval and adherence to good clinical practice by itself (Sponsor).
Interim analysis: Several meta-analyses of the effect of rTMS/iTBS on negative symptoms in schizophrenia showing heterogeneous effect sizes have been published since begin of the trial. Thefore, an interim analysis after inclusion of at least 15 patients in each arm was added to the protocol. In case of null findings and low effect sizes (no differences of either rTMS or TBS vs. sham in the primary outcome), the trial will be terminated.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
repetitive transcranial magnetic stimulation
theta burst stimulation
placebo transcranial magnetic stimulation
Time frame: 4 weeks
negative symptoms in schizophrenia with 25 items and a range 0-125 with higher score representing more symptoms
Time frame: 2 weeks, 4 weeks, 12 weeks
negative symptoms in schizophrenia with 25 items and a range 0-125 with higher score representing more symptoms
Time frame: 2 weeks, 4 weeks, 12 weeks
positive and negative symptoms in schizophrenia with 30 items and a range 30-210 with higher scores representing more symptoms (total score, score for positive, negative symptoms and for general psychopathology)
Time frame: 2 weeks, 4 weeks, 12 weeks
Calgary Depression Scale for Schizophrenia
Time frame: 2 weeks, 4 weeks, 12 weeks
measure of overall symptom severity and treatment response on a scale 1-7 with higher scores presenting more symptoms
Time frame: 2 weeks, 4 weeks, 12 weeks
measurment of depressivity: 10 items with a range 0-50 and higher values indicating higher scores
Time frame: 2 weeks, 4 weeks, 12 weeks
measurment of depressivity: 21 items with a range 0-65 and higher values indicating higher scores
Time frame: 4 weeks, 12 weeks
test for short-term and working memory
Time frame: 4 weeks, 12 weeks
test of attention for measurement of concentration
Time frame: 4 weeks
measurement of resting state electrophysiologic activity as indicated by frequency analysis and rTMS-evoked activity
Time frame: 4 weeks
structural, anatomical, diffusion weighted magnetic resonance imaging
Time frame: 4 weeks, 12 weeks
number of smoked cigarettes per week
University of Regensburg
Other
Acronym: RADOVAN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04024371
Anhedonia, Anhedonia, Physical
Frankfurt, Germany
View Trial DetailsNCT04789915
Mental Disorders, Negative Symptoms With Primary Psychotic Disorder
Glostrup Municipality, Capitol Region, Denmark
View Trial DetailsNCT05527210
Mental Disorders, Psychotic Disorders
Catonsville, Maryland, United States
View Trial DetailsNCT00001246
Attention Deficit Disorder With Hyperactivity, Attention Deficit Disorder with Hyperactivity
Bethesda, Maryland, United States
View Trial Details